Literature DB >> 23332085

Guidelines for the Management of Hepatitis C Virus Infection: First edition, May 2012, The Japan Society of Hepatology.

.   

Abstract

Entities:  

Year:  2013        PMID： 23332085     DOI： 10.1111/hepr.12020

Source DB:  PubMed          Journal:  Hepatol Res        ISSN： 1386-6346            Impact factor:   4.288


× No keyword cloud information.
  22 in total

1.  Extended therapy duration for therapy-refractory hepatitis C patients with genotype 2.

Authors:  Ken Sato; Masatoshi Yanagisawa; Hiroaki Hashizume; Yuichi Yamazaki; Norio Horiguchi; Satoru Kakizaki; Masatomo Mori
Journal:  World J Gastroenterol       Date:  2013-09-14       Impact factor: 5.742

Review 2.  Hepatitis C virus genetic variability and evolution.

Authors:  Natalia Echeverría; Gonzalo Moratorio; Juan Cristina; Pilar Moreno
Journal:  World J Hepatol       Date:  2015-04-28

3.  Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.

Authors:  Tsugiko Oze; Naoki Hiramatsu; Takayuki Yakushijin; Masanori Miyazaki; Sadaharu Iio; Masahide Oshita; Hideki Hagiwara; Eiji Mita; Yoshiaki Inui; Taizo Hijioka; Masami Inada; Shinji Tamura; Harumasa Yoshihara; Atsuo Inoue; Yasuharu Imai; Takuya Miyagi; Yuichi Yoshida; Tomohide Tatsumi; Tatsuya Kanto; Akinori Kasahara; Norio Hayashi; Tetsuo Takehara
Journal:  J Gastroenterol       Date:  2013-05-21       Impact factor: 7.527

4.  Prognostic effect of response to interferon therapy after laparoscopic splenectomy among patients with marked thrombocytopenia and hepatitis C virus-related cirrhosis.

Authors:  Hideyuki Tamai; Yoshiyuki Mori; Naoki Shingaki; Ryo Shimizu; Jyunya Nuta; Kosaku Moribata; Yoshimasa Maeda; Yosuke Muraki; Hisanobu Deguchi; Izumi Inoue; Takao Maekita; Mikitaka Iguchi; Jun Kato; Katsunari Takifuji; Hiroki Yamaue; Masao Ichinose
Journal:  Hepatol Int       Date:  2014-11-01       Impact factor: 6.047

5.  Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study.

Authors:  Noritomo Shimada; Hidenori Toyoda; Akihito Tsubota; Tatsuya Ide; Koichi Takaguchi; Keizo Kato; Masaki Kondoh; Kazuhiro Matsuyama; Takashi Kumada; Michio Sata
Journal:  J Gastroenterol       Date:  2013-11-28       Impact factor: 7.527

6.  Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching.

Authors:  Hideki Fujii; Takeshi Nishimura; Atsushi Umemura; Taichiro Nishikawa; Kanji Yamaguchi; Michihisa Moriguchi; Yoshio Sumida; Hironori Mitsuyoshi; Chihiro Yokomizo; Saiyu Tanaka; Hiroki Ishikawa; Kenichi Nishioji; Hiroyuki Kimura; Shiro Takami; Yasuyuki Nagao; Takayuki Takeuchi; Toshihide Shima; Yoshihiko Sawa; Masahito Minami; Kohichiroh Yasui; Yoshito Itoh
Journal:  World J Hepatol       Date:  2015-12-08

7.  Comparison of peginterferon alfa-2a and alfa-2b for treatment of patients with chronic hepatitis C: a retrospective study using the Japanese Interferon Database.

Authors:  Izumi Sato; Takuro Shimbo; Yohei Kawasaki; Naohiko Masaki
Journal:  Drug Des Devel Ther       Date:  2014-12-30       Impact factor: 4.162

8.  Treatment of hepatitis C virus infection in the future.

Authors:  Tatsuo Kanda; Osamu Yokosuka; Masao Omata
Journal:  Clin Transl Med       Date:  2013-04-11

9.  Metabolome analysis of erythrocytes from patients with chronic hepatitis C reveals the etiology of ribavirin-induced hemolysis.

Authors:  Tetsuru Karasawa; Takafumi Saito; Yoshiyuki Ueno; Masahiro Sugimoto; Tomoyoshi Soga
Journal:  Int J Med Sci       Date:  2013-09-09       Impact factor: 3.738

Review 10.  Hepatitis C virus NS3 inhibitors: current and future perspectives.

Authors:  Kazi Abdus Salam; Nobuyoshi Akimitsu
Journal:  Biomed Res Int       Date:  2013-10-27       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.